Liminatus Pharma Faces Delisting Concerns
Ticker: LIMNW · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1971387
| Field | Detail |
|---|---|
| Company | Liminatus Pharma, Inc. (LIMNW) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Liminatus Pharma might get delisted - big trouble for shareholders.
AI Summary
Liminatus Pharma, Inc. filed an 8-K on June 4, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as Iris Parent Holding Corp. until March 28, 2023, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential issues with Liminatus Pharma's continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Numbers
- 001-42626 — SEC File Number (Identifies the company's filing with the SEC.)
- 93-2710748 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Liminatus Pharma, Inc. (company) — Registrant
- Iris Parent Holding Corp. (company) — Former company name
- March 28, 2023 (date) — Date of name change
- May 29, 2025 (date) — Earliest event reported date
- June 4, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 6 Centerpointe Drive #625, La Palma, CA 90623 (address) — Business and mailing address
FAQ
What specific listing rule or standard has Liminatus Pharma failed to satisfy?
The filing does not specify the exact listing rule or standard that Liminatus Pharma has failed to satisfy, only that a notice has been issued.
What is the expected timeline for addressing the delisting concerns?
The filing does not provide a timeline for addressing the delisting concerns.
Has Liminatus Pharma taken any steps to rectify the situation leading to the delisting notice?
The filing does not detail any specific steps taken by Liminatus Pharma to rectify the situation.
What is the potential impact on shareholders if the company is delisted?
Delisting typically results in reduced liquidity for shares and can negatively impact their market value, making them harder to trade.
When did Liminatus Pharma change its name from Iris Parent Holding Corp.?
Liminatus Pharma, Inc. changed its name from Iris Parent Holding Corp. on March 28, 2023.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Liminatus Pharma, Inc. (LIMNW).